Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07710716 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients

Study acronym: CATTALYST
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 9 months later Sep 30, 2026 → Jun 30, 2028
See other at-risk trials from Novartis

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 30, 2026 to Jun 30, 2028
    • Primary endpoints: details revised at 1 of 17 entries
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 8 of 45 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 34 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
The aim of this study is to assess the clinical adoption, treatment patterns, and safety of adjuvant ribociclib use in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) patients. This is a multi-country study using secondary real-world data sources.
Trial Details
NCT Number NCT07710716
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 3,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov